CORTIMENT®’s multimatrix structure (MMX®) is designed to deliver budesonide topically throughout the entire colon1-4
Phase 1
CORTIMENT® is coated with a gastro-resistant film, delaying budesonide release until a pH >7. This protects budesonide during transit through the stomach and duodenum up to the lower part of the intestine.3
Phase 2
Inside the tablet, budesonide is mixed with a hydrophilic matrix. Once the tablet comes into contact with the intestinal fluids it swells.3
Phase 3
The hydrophilic matrix gradually dissolves resulting in the release of budesonide from the inert lilophilic matrices in a controlled fashion throughout the entire colon.3
COMPONENTS OF THE MMX® SYSTEM5,6
Protective gastro-resistant coat
Protects active ingredient from degradation in upper GI tract and delays its release until the tablet reaches the colon.
Hydrophilic matrix
Interacts with GI fluids to form an outer viscous gel mass, which slows diffusion of active ingredient from core.
Inert lipophilic matrix
Slows penetration of GI fluids into tablet core.
GI = gastrointestinal
MMX® TECHNOLOGY1,5
Enables targeted delivery of
CORTIMENT® to the full length
of the colon.
A single-dose pharmacokinetic study
demonstrated that CORTIMENT®‘s colonic
release system is suitable for targeting
the whole colon.
Helps delay and extend the release
of drug.
Budesonide MMX® was detected by
scintigraphic imaging in the ascending
colon between 4 and >24 hours after
dosing.
Active substances are protected from
the acidic pH and enzymes of the upper
digestive tract.
MMX = multimatrix
CORTIMENT® RELEASE 7 HOURS AFTER DRUG ADMINISTRATION5
Adapted from Brunner M, et al. Br J Clin Pharmacol. 2006;61:31-8.
CORTIMENT® IS RELEASED THROUGHOUT THE COLON WITHIN 24 HOURS1,7
~96% of CORTIMENT® absorption takes place in the ascending and descending colon1
Adapted from Data on file. Ferring UK Ltd. 7
Ensure your patients are prescribed the only licensed oral budesonide for mild to moderate UC flares where 5-ASA is insufficient
CORTIMENT® contains the well known corticosteroid budesonide, which reduces inflammation within the colon that arises during a flare8
CORTIMENT® is encased within a gastro-resistant coating that protects the active ingredient from the acidic pH of the upper GI tract8
The MMX® technology then releases budesonide at a controlled rate enabling targeted delivery of budesonide throughout the entire length of the colon, whilst minimising systemic absorption1-4,8
Brunner M, et al. Br J Clin Pharmacol. 2006;61(1):31–8.
Travis SPL, et al. Gut. 2014;63:433–41. doi:10.1136/gutjnl-2012-304258.
Fiorino G, et al. Curr Med Chem. 2010;17(17):1851–7.
Sandborn WJ, et al. Gastroenterology. 2012;143:1218–1226.
Danese S, et al. J Crohns Colitis. 2019;13(supplement 1):296–297.
Job Code: UK-COR-2200001 - Date of preparation: January 2022
Our use of cookies
We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.
Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.
Necessary cookies
Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.
Analytics cookies
We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.
